GLP-1 Access and Transparency
Pairing high-quality, compounded medications with powerful lifestyle change is in the public interest.
GLP-1
Access and
Transparency
Pairing high-quality, compounded medications with powerful lifestyle
change is in the public interest.
Obesity is an epidemic.
7 in 10
have obesity or are overweight1
5 in 10
are interested in weight loss drugs2
1 in 4
will be considered severely obese by 20303
Brand-name meds are scarce and expensive in the United States.
It’s a fact that brand-name GLP-1 medications are cost-prohibitive and difficult to obtain. That’s why Noom offers both brand-name and compounded medications to give our customers more options to get the medications they need. Our mission is to empower everyone, everywhere to live better longer – not only those with great insurance.
$1,349
US list price of a popular GLP-1 medication4
$137
Price of the same drug in Germany5
$149
The starting price of Noom GLP-1Rx
Safety is paramount.
cGMP Regulations
503B facilities are held to a higher standard. They must comply with the FDA’s current Good Manufacturing Practices (cGMP) – the same standards as the pharmaceutical companies manufacturing brand-name medications.
Fill Line Machine
The facility uses robotic, aseptic fill machines. The quality control process involves AI automated scanning for ingredients and contaminants, ensuring consistency and sterility.
Certificate of Analysis (COA)
Noom Med patients prescribed compounded medication may request a COA from their care coordination team (careteam@noom.com), providing utmost transparency as to the ingredients and quality of each batch of medication. A COA is a document provided by a 503B outsourcing facility showing that the medication meets regulatory requirements.
Our intake process:
We verify the identity of every patient.
We require a full-body photo before treatment.
We require a comprehensive medical intake.
We verify the identity of every patient.
We require a full-body photo before treatment.
We require a comprehensive medical intake.
Medication alone is not enough.
INDICATIONS AND USAGE
WEGOVY® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity:
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (1).
- to reduce excess body weight and maintain weight reduction long term in:
- Adults and pediatric patients aged 12 years and older with obesity
- Adults with overweight in the presence of at least one weight-related comorbid condition (1).
It says so right on the label: GLP-1s are to be used “in combination with a reduced calorie diet and increased physical activity.”
Behavior change combined with GLP-1s drives lasting weight loss.
Absent behavior change, most of the lost weight will come back within 12 months of stopping the med.
Behavior Change Group Maintains Weight Loss Better7
6 out of 7 people stop taking GLP-1s8.
The vast majority of people stop taking their GLP-1 meds by month 24. That’s why having a companion program is vital to maintaining weight loss success.
Powerful meds need a powerful companion.
Keep the muscle, lose the fat
Develop healthy habits
Find support in community
Ask your 1:1 coach anything
Noom GLP-1Rx Taper Off Guarantee
Our Experts
Noom Clinical Leadership
Adonis Saremi
Chief Medical Officer
Dr. Adonis Saremi, MD holds triple board certification in Internal Medicine, Clinical Informatics and Obesity Medicine. Dr. Saremi is focused on driving dynamic results and acuity in digital health.
He received his B.S. from the University of California, Riverside, and his MS in Applied Physiology and MD from Rosalind Franklin University of Medicine and Science. Dr. Saremi completed his residency in Internal Medicine at UC San Diego and has taught at the Veteran’s Affairs (VA) hospital with UC Irvine School of Medicine. Dr. Saremi’s expertise in scaling physician service to put patient needs at the center is evidenced by his work with telehealth start-ups and the Medical Board of California. He serves as a Judge for the Digital Health Hub awards held at the annual HLTH conference and on the Clinician Council of the American Telehealth Association (ATA).
Julia Edelman
Executive Director of Women’s Health
Julia Schlam Edelman, MD is a gynecologist, author, and public speaker. An expert in menopause and women’s health, Dr. Edelman has written two books for patients and their physicians: Menopause Matters: Your Guide to a Long and Healthy Life (John Hopkins University Press) and Successful Sleep Strategies for Women (Harvard Health Publications).
After earning a BS from Yale, and an MD at Columbia University’s College of Physicians and Surgeons, Dr. Edelman completed an OB/GYN residency at Brigham and Women’s Hospital. Dr. Edelman has taught at both Harvard and Brown University Medical Schools, and served as a clinical consultant at the Massachusetts General Hospital. She served on the Board of Trustees of the Massachusetts Medical Society for ten years. Massachusetts Medical Society selected Dr. Edelman as their Clinician of the Year in 2018.
Dr. Edelman has operated a solo, private practice in Southeastern Massachusetts for over 25 years. Named “Menopause Clinician of the Year” by The North American Menopause Society in 2010, Dr. Edelman enjoys speaking with women about the latest developments in women’s health. Her new book The Savvy Woman’s Guide to Menopause: Before, During, and Beyond will be published by Johns Hopkins University Press in 2025.
Karen Mann
Medical Director
Dr. Karen Mann is a board-certified OB/GYN who received her medical degree from The George Washington University School of Medicine and completed her residency at Kaiser Permanente, Los Angeles Medical Center.
Dr. Mann also holds a BA in Sociology from UCLA, graduating Summa Cum Laude. With over a decade of experience in caring for women, her focus has been on family planning at FPA Women’s Health in California, where she also led the “Weigh to Wellness” weight loss program, managed their prenatal program, and spearheaded their telehealth platform, which has been running for nearly five years. Dr. Mann is a diplomate of the American Board of Obesity Medicine and a certified menopause practitioner (MSCP) through The Menopause Society.
Committed to ongoing education, she has studied nutrition science at Stanford and integrative nutrition through the Integrative and Functional Nutrition Academy. She became a certified life coach and strives to incorporate mindfulness-based stress reduction and trauma-informed care into her practice, living her mission of empowering individuals to achieve their health goals through a compassionate and holistic approach.
Yalda Olcott
Head of Healthcare Operations
Ms. Olcott holds a Doctor of Pharmacy degree from North Dakota State University and brings over a decade of pharmacy leadership experience, including retail pharmacy, medication therapy management (MTM), and pharmacy benefits management (PBM). Ms. Olcott’s extensive PBM experience includes utilization management, formulary development, clinical program development, and maintaining client relationships.
Most recently, Ms. Olcott held the role of VP Operations and Account Services at ClearScript. In this role, she led oversight and strategy of clinical programs, clinical services, product development, client relationships, and vendor management. At Prime Therapeutics, she held many leadership roles, was heavily involved in utilization management and medication therapy management, and maintained client relationships while delivering cost-effective solutions for employers and health plans.
Noom Science Advisory Board
Shawn Cole
Dr. Cole is double board certified in internal medicine where he completed his training at Yale-New Haven Hospital and in obesity medicine and has long standing experience as a leader in academic primary care, telehealth, population health, and in obesity medicine.
Dr. Cole has a passion for combining evidence-based practice with innovative healthcare strategies that enable greater access to medical treatment for the optimization of chronic disease management. Holding Masters degrees in both Applied Nutrition and in Health Administration, Dr. Cole’s maintains a strong clinical leadership emphasis on utilizing an interprofessional, health technology-driven approach to improve outcomes in obesity.
Lindsey Connors
Lindsey Connors, PharmD is a highly skilled pharmacist with a diverse focus including long-term care, compounding pharmacy, consulting, clinical research, and technical writing.
Lindsey received specialized training in sterile compounding from Critical Point and has honed her skills through extensive experience in busy 503a compounding pharmacies. Lindsey has developed regulatory-compliant quality systems tailored for smaller pharmacies and has guided clients through the complexities of regulatory agencies such as the NABP, FDA, and various state boards of pharmacies. Her expertise extends to managing teams of professionals and support staff while overseeing the fiscal management of pharmacy operations. Known for her ability to build cohesive teams by balancing diverse perspectives and working towards shared objectives, Lindsey is licensed in Alabama, Florida, Illinois, Maryland, Michigan, Oklahoma, Texas, and Virginia.
Dr. Pouran Faghri
Dr. Pouran Faghri is an Adjunct Full Professor in the Department of Environmental Health Sciences at the Fielding School of Public Health, University of California, Los Angeles.
As a pioneer in behavioral interventions for weight loss and maintenance, Dr. Faghri’s work includes the application of cognitive-behavioral techniques and social support to improve self-regulation, enhance self-efficacy, and increase self-control. Dr. Faghri has also employed strategies from behavioral economics and contingency management for effective weight management. As an occupational health expert, Dr. Faghri’s comprehensive research portfolio encompasses the study of occupational health and safety, examining workplace stressors and their impact on chronic diseases such as mental health issues, cardiovascular conditions, obesity, and type 2 diabetes. A sought-after speaker at national and international conferences, she shares insights on public health advancements and strategies for promoting healthy living.
Andrew Gostine
Andrew Gostine, MD, MBA, is an accomplished healthcare professional passionate about leveraging artificial intelligence in the clinical setting.
As a co-founder and the CEO of Artisight, Dr. Gostine is at the forefront of fusing deep learning and IoT sensors to facilitate healthcare automation and optimization.
Dr. Gostine’s journey began as a critical care anesthesiologist, where he gained valuable insights into the evolving needs of practicing clinicians in the ICUs and operating rooms. This firsthand experience inspired him to establish Artisight with a vision to address real problems in hospital workflow to improve overall efficiencies.
Beyond his entrepreneurial pursuits, Dr. Gostine remains actively engaged in clinical practice. This dedication allows him to stay up-to-date with clinicians’ changing and dynamic needs, bridging the gap between technological advancements and their practical applications in healthcare.
Noom Partners in Safety
News and Updates
Noom Launches Affordable, High-quality Compounded GLP-1 Solution, Expanding GLP-1 Access in the United States
Footnotes
- https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity
- https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-july-2023-the-publics-views-of-new-prescription-weight-loss-drugs-and-prescription-drug-costs/
- https://news.harvard.edu/gazette/story/2019/12/close-to-half-of-u-s-population-projected-to-have-obesity-by-2030/
- https://www.sanders.senate.gov/wp-content/uploads/Letter-from-Sen.-Bernard-Sanders-to-Novo-Nordisk.pdf
- https://www.sanders.senate.gov/wp-content/uploads/Wegovy-report-FINAL.pdf
- https://pharmanewsintel.com/features/addressing-muscle-loss-associated-with-glp-1-medication-use#:~:text=%E2%80%9CAnywher[…]muscle%20plays.%E2%80%9D
- https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00054-3/fulltext
- https://www.reuters.com/business/healthcare-pharmaceuticals/most-patients-stop-using-wegovy-ozempic-weight-loss-within-two-years-analysis-2024-07-10/
- *The FDA does not review any compounded medication for safety and efficacy.